Learning Objectives:

1. Discuss treatment options for first-line metastatic renal cell carcinoma (RCC)

2.  Discuss results of study evaluating provider preferences when choosing between dual immunotherapy vs. immunotherapy/tyrosine kinase inhibitors in metastatic RCC

3.  Review use of abiraterone in prostate cancer. Discuss rationale and study design for abiraterone 500 mg QOD dose de-escalation trial.

Session date: 
11/01/2021 - 12:00pm to 1:00pm CDT
Location: 
Virtually
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Priyanka Chablani, MD